Personal information

No personal information available

Activities

Works (50 of 74)

Items per page:
Page 1 of 2

Microsatellite instability and survival after adjuvant chemotherapy among stage II and III colon cancer patients: results from a population-based study.

Molecular oncology
2019-12 | Journal article
Contributors: Alwers E; Jansen L; Bläker H; Kloor M; Tagscherer KE; Roth W; Boakye D; Herpel E; Grüllich C; Chang-Claude J et al.
Source: Self-asserted source
Carsten Grüllich via Europe PubMed Central

Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma.

European journal of cancer (Oxford, England : 1990)
2019-12 | Journal article
Contributors: Donskov F; Motzer RJ; Voog E; Hovey E; Grüllich C; Nott LM; Cuff K; Gil T; Jensen NV; Chevreau C et al.
Source: Self-asserted source
Carsten Grüllich via Europe PubMed Central

Serum very long-chain fatty acid-containing lipids predict response to immune checkpoint inhibitors in urological cancers.

Cancer immunology, immunotherapy : CII
2019-11 | Journal article
Contributors: Mock A; Zschäbitz S; Kirsten R; Scheffler M; Wolf B; Herold-Mende C; Kramer R; Busch E; Jenzer M; Jäger D et al.
Source: Self-asserted source
Carsten Grüllich via Europe PubMed Central

The BRCA2 mutation status shapes the immune phenotype of prostate cancer.

Cancer immunology, immunotherapy : CII
2019-09 | Journal article
Contributors: Jenzer M; Keß P; Nientiedt C; Endris V; Kippenberger M; Leichsenring J; Stögbauer F; Haimes J; Mishkin S; Kudlow B et al.
Source: Self-asserted source
Carsten Grüllich via Europe PubMed Central

[Molecular tumor board prostate cancer].

Der Urologe. Ausg. A
2019-07 | Journal article
Contributors: Seitz AK; Heck MM; Kamer MW; Grüllich C
Source: Self-asserted source
Carsten Grüllich via Europe PubMed Central

Tumor response to irinotecan is associated with CYP3A5 expression in colorectal cancer.

Oncology letters
2019-02 | Journal article
Contributors: Buck E; Sprick M; Gaida MM; Grüllich C; Weber TF; Herpel E; Bruckner T; Koschny R
Source: Self-asserted source
Carsten Grüllich via Europe PubMed Central

Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate.

Oncotarget
2019-01 | Journal article
Contributors: Apostolidis L; Nientiedt C; Winkler EC; Berger AK; Kratochwil C; Kaiser A; Becker AS; Jäger D; Hohenfellner M; Hüttenbrink C et al.
Source: Self-asserted source
Carsten Grüllich via Europe PubMed Central

Correlation between genomic index lesions and mpMRI and 68Ga-PSMA-PET/CT imaging features in primary prostate cancer.

Scientific Reports
2018-11 | Journal article
Contributors: Kesch C; Radtke JP; Wintsche A; Wiesenfarth M; Luttje M; Gasch C; Dieffenbacher S; Pecqueux C; Teber D; Hatiboglu G et al.
Source: Self-asserted source
Carsten Grüllich via Europe PubMed Central

Early metabolic response in sequential FDG-PET/CT under cetuximab is a predictive marker for clinical response in first-line metastatic colorectal cancer patients: results of the phase II REMOTUX trial.

British journal of cancer
2018-07 | Journal article
Contributors: Berger AK; Lücke S; Abel U; Haag GM; Grüllich C; Stange A; Dietrich M; Apostolidis L; Freitag A; Trierweiler C et al.
Source: Self-asserted source
Carsten Grüllich via Europe PubMed Central

FGF-2 is a driving force for chromosomal instability and a stromal factor associated with adverse clinico-pathological features in prostate cancer.

Urologic oncology
2018-06 | Journal article
Contributors: Pecqueux C; Arslan A; Heller M; Falkenstein M; Kaczorowski A; Tolstov Y; Sültmann H; Grüllich C; Herpel E; Duensing A et al.
Source: Self-asserted source
Carsten Grüllich via Europe PubMed Central

Genomic features of renal cell carcinoma with venous tumor thrombus.

Scientific reports
2018-05 | Journal article
Contributors: Warsow G; Hübschmann D; Kleinheinz K; Nientiedt C; Heller M; Van Coile L; Tolstov Y; Trennheuser L; Wieczorek K; Pecqueux C et al.
Source: Self-asserted source
Carsten Grüllich via Europe PubMed Central

Testicular choriocarcinoma with cutaneous metastasis in a 19-year-old man.

Journal of cutaneous pathology
2018-05 | Journal article
Contributors: Toberer F; Enk A; Hartschuh W; Grüllich C
Source: Self-asserted source
Carsten Grüllich via Europe PubMed Central

Survival outcomes of patients with germ cell tumors treated with high-dose chemotherapy for refractory or relapsing disease.

Oncotarget
2018-04 | Journal article
Contributors: Zschäbitz S; Distler FA; Krieger B; Wuchter P; Schäfer-Eckart K; Jenzer M; Hohenfellner M; Dreger P; Haag GM; Jäger D et al.
Source: Self-asserted source
Carsten Grüllich via Europe PubMed Central

Prospective single center trial of next-generation sequencing analysis in metastatic renal cell cancer: the MORE-TRIAL.

Future science OA
2018-03 | Journal article
Contributors: Dieffenbacher S; Zschäbitz S; Hofer L; Hatiboglu G; Hou W; Hohenfellner M; Duensing S; Sültmann H; Pahernik S; Grüllich C
Source: Self-asserted source
Carsten Grüllich via Europe PubMed Central

Cabozantinib: Multi-kinase Inhibitor of MET, AXL, RET, and VEGFR2.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer
2018-01 | Journal article
Contributors: Grüllich C
Source: Self-asserted source
Carsten Grüllich via Europe PubMed Central

Lenvantinib: A Tyrosine Kinase Inhibitor of VEGFR 1-3, FGFR 1-4, PDGFRα, KIT and RET.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer
2018-01 | Journal article
Contributors: Zschäbitz S; Grüllich C
Source: Self-asserted source
Carsten Grüllich via Europe PubMed Central

Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapy.

Urologic oncology
2017-12 | Journal article
Contributors: Chen X; Bernemann C; Tolkach Y; Heller M; Nientiedt C; Falkenstein M; Herpel E; Jenzer M; Grüllich C; Jäger D et al.
Source: Self-asserted source
Carsten Grüllich via Europe PubMed Central

[Immunotherapy as modern tumor treatment].

Der Radiologe
2017-10 | Journal article
Contributors: Grüllich C
Source: Self-asserted source
Carsten Grüllich via Europe PubMed Central

Results of a Patient Survey for Assessment Services in Renal Transplant Patients With a History of Cancer.

Progress in transplantation (Aliso Viejo, Calif.)
2017-09 | Journal article
Contributors: Ihrig A; Maatouk I; Fink S; Pahernik S; Süsal C; Huber J; Hohenfellner M; Zeier M; Grüllich C
Source: Self-asserted source
Carsten Grüllich via Europe PubMed Central

[Level IV inferior vena cava tumor thrombus : A rare diagnosis in patients with renal cell carcinoma].

Der Urologe. Ausg. A
2017-07 | Journal article
Contributors: Hofer L; Gasch C; Hatiboglu G; Motsch J; Grüllich C; Duensing S; Hohenfellner M
Source: Self-asserted source
Carsten Grüllich via Europe PubMed Central

Mutations in BRCA2 and taxane resistance in prostate cancer.

Scientific reports
2017-07 | Journal article
Contributors: Nientiedt C; Heller M; Endris V; Volckmar AL; Zschäbitz S; Tapia-Laliena MA; Duensing A; Jäger D; Schirmacher P; Sültmann H et al.
Source: Self-asserted source
Carsten Grüllich via Europe PubMed Central

Resistance training as supportive measure in advanced cancer patients undergoing TKI therapy-a controlled feasibility trial.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
2017-06 | Journal article
Contributors: Rosenberger F; Wiskemann J; Vallet S; Haag GM; Schembri E; Jäger D; Grüllich C
Source: Self-asserted source
Carsten Grüllich via Europe PubMed Central

Patient-specific molecular alterations are associated with metastatic clear cell renal cell cancer progressing under tyrosine kinase inhibitor therapy.

Oncotarget
2017-05 | Journal article
Contributors: Dietz S; Sültmann H; Du Y; Reisinger E; Riediger AL; Volckmar AL; Stenzinger A; Schlesner M; Jäger D; Hohenfellner M et al.
Source: Self-asserted source
Carsten Grüllich via Europe PubMed Central

The PAZOREAL noninterventional study to assess effectiveness and safety of pazopanib and everolimus in the changing metastatic renal cell carcinoma treatment landscape.

Future oncology (London, England)
2017-05 | Journal article
Contributors: Goebell PJ; Doehn C; Grüllich C; Grünwald V; Steiner T; Ehneß R; Welslau M
Source: Self-asserted source
Carsten Grüllich via Europe PubMed Central

Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation.

European journal of cancer (Oxford, England : 1990)
2017-03 | Journal article
Contributors: Zschäbitz S; Lasitschka F; Hadaschik B; Hofheinz RD; Jentsch-Ullrich K; Grüner M; Jäger D; Grüllich C
Source: Self-asserted source
Carsten Grüllich via Europe PubMed Central

Efficacy of Cabazitaxel Treatment in Metastatic Castration Resistant Prostate Cancer in Second and Later Lines. An Experience from Two German Centers.

Journal of Cancer
2017-02 | Journal article
Contributors: Zschäbitz S; Vallet S; Hadaschik B; Debatin D; Fuxius S; Karcher A; Pahernik S; Spath C; Duensing S; Jäger D et al.
Source: Self-asserted source
Carsten Grüllich via Europe PubMed Central

MET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive marker.

Oncotarget
2017-01 | Journal article
Contributors: Macher-Goeppinger S; Keith M; Endris V; Penzel R; Tagscherer KE; Pahernik S; Hohenfellner M; Gardner H; Grüllich C; Schirmacher P et al.
Source: Self-asserted source
Carsten Grüllich via Europe PubMed Central

PARP inhibition in BRCA2-mutated prostate cancer.

Annals of oncology : official journal of the European Society for Medical Oncology
2017-01 | Journal article
Contributors: Nientiedt C; Tolstov Y; Volckmar AL; Endris V; Bonekamp D; Haberkorn U; Jäger D; Sültmann H; Stenzinger A; Hohenfellner M et al.
Source: Self-asserted source
Carsten Grüllich via Europe PubMed Central

Effective downsizing but enhanced intratumoral heterogeneity following neoadjuvant sorafenib in patients with non-metastatic renal cell carcinoma.

Langenbeck's archives of surgery
2016-12 | Journal article
Contributors: Hatiboglu G; Hohenfellner M; Arslan A; Hadaschik B; Teber D; Radtke JP; Hallscheidt P; Tolstov Y; Roth W; Grüllich C et al.
Source: Self-asserted source
Carsten Grüllich via Europe PubMed Central

Impact of resection and systemic therapy on the survival of patients with brain metastasis of metastatic renal cell carcinoma.

Journal of neuro-oncology
2016-08 | Journal article
Contributors: Du Y; Pahernik S; Hadaschik B; Teber D; Duensing S; Jäger D; Hohenfellner M; Grüllich C
Source: Self-asserted source
Carsten Grüllich via Europe PubMed Central

Spatial niche formation but not malignant progression is a driving force for intratumoural heterogeneity.

Nature communications
2016-06 | Journal article
Contributors: Hoefflin R; Lahrmann B; Warsow G; Hübschmann D; Spath C; Walter B; Chen X; Hofer L; Macher-Goeppinger S; Tolstov Y et al.
Source: Self-asserted source
Carsten Grüllich via Europe PubMed Central

Survival and prognostic factors of patients with renal cell cancer with bone metastasis in the era of targeted therapy: A single-institution analysis.

Urologic oncology
2016-06 | Journal article
Contributors: Du Y; Pahernik S; Hadaschik B; Teber D; Duensing S; Jäger D; Hohenfellner M; Grüllich C
Source: Self-asserted source
Carsten Grüllich via Europe PubMed Central

Activity of immune checkpoint inhibition in platinum refractory germ-cell tumors.

Annals of oncology : official journal of the European Society for Medical Oncology
2016-03 | Journal article
Contributors: Zschäbitz S; Lasitschka F; Jäger D; Grüllich C
Source: Self-asserted source
Carsten Grüllich via Europe PubMed Central

Local Recurrence After Curative Surgical Treatment of Renal Cell Cancer: A Study of 91 Patients.

Clinical genitourinary cancer
2016-02 | Journal article
Contributors: Du Y; Grüllich C; Hadaschik B; Hatiboglu G; Hohenfellner M; Pahernik S
Source: Self-asserted source
Carsten Grüllich via Europe PubMed Central

Local salvage therapy for late (≥2 years) metastatic and local relapse of renal cell cancer is a potentially curative treatment irrespective of the site of recurrence.

Urologic oncology
2015-12 | Journal article
Contributors: Grüllich C; Vallet S; Hecht C; Duensing S; Hadaschik B; Jäger D; Hohenfellner M; Pahernik S
Source: Self-asserted source
Carsten Grüllich via Europe PubMed Central

Prognostic Significance and Functional Role of CEP57 in Prostate Cancer.

Translational oncology
2015-12 | Journal article
Contributors: Mang J; Korzeniewski N; Dietrich D; Sailer V; Tolstov Y; Searcy S; von Hardenberg J; Perner S; Kristiansen G; Marx A et al.
Source: Self-asserted source
Carsten Grüllich via Europe PubMed Central

Uncoupling of PUMA Expression and Apoptosis Contributes to Functional Heterogeneity in Renal Cell Carcinoma - Prognostic and Translational Implications.

Translational oncology
2015-12 | Journal article
Contributors: Zhou X; Li J; Marx C; Tolstov Y; Rauch G; Herpel E; Macher-Goeppinger S; Roth W; Grüllich C; Pahernik S et al.
Source: Self-asserted source
Carsten Grüllich via Europe PubMed Central

Cooperation of BRAF(F595L) and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling.

Leukemia
2015-11 | Journal article
Contributors: Kordes M; Röring M; Heining C; Braun S; Hutter B; Richter D; Geörg C; Scholl C; Gröschel S; Roth W et al.
Source: Self-asserted source
Carsten Grüllich via Europe PubMed Central

Steroid responsive encephalopathy associated with autoimmune thyroiditis following ipilimumab therapy: a case report.

BMC research notes
2015-07 | Journal article
Contributors: Carl D; Grüllich C; Hering S; Schabet M
Source: Self-asserted source
Carsten Grüllich via Europe PubMed Central

[Intratumoral heterogeneity in renal cell carcinoma. Molecular basis and translational implications].

Der Urologe. Ausg. A
2015-06 | Journal article
Contributors: Höfflin R; Roth W; Sültmann H; Grüllich C; Hatiboglu G; Nyarangi-Dix J; Schönberg G; Teber D; Hadaschik B; Pahernik S et al.
Source: Self-asserted source
Carsten Grüllich via Europe PubMed Central

Features of cell death, mitochondrial activation and caspase dependence of rabbit anti-T-lymphocyte globulin signaling in lymphoblastic Jurkat cells are distinct from classical apoptosis signaling of CD95.

Leukemia & lymphoma
2015-05 | Journal article
Contributors: Ziegler C; Finke J; Grüllich C
Source: Self-asserted source
Carsten Grüllich via Europe PubMed Central

Efficacy of targeted treatment beyond third-line therapy in metastatic kidney cancer: retrospective analysis from a large-volume cancer center.

Clinical genitourinary cancer
2014-12 | Journal article
Contributors: Vallet S; Pahernik S; Höfner T; Tosev G; Hadaschik B; Duensing S; Sedlaczek O; Hohenfellner M; Jäger D; Grüllich C et al.
Source: Self-asserted source
Carsten Grüllich via Europe PubMed Central

Harnessing the p53-PUMA axis to overcome DNA damage resistance in renal cell carcinoma.

Neoplasia (New York, N.Y.)
2014-12 | Journal article
Contributors: Zhou X; Tolstov Y; Arslan A; Roth W; Grüllich C; Pahernik S; Hohenfellner M; Duensing S
Source: Self-asserted source
Carsten Grüllich via Europe PubMed Central

Interdisciplinary counseling service for renal malignancies: a patient-centered approach to raise guideline adherence.

Urologic oncology
2014-10 | Journal article
Contributors: Huber J; Ihrig A; Winkler E; Brechtel A; Friederich HC; Herzog W; Frank M; Grüllich C; Hallscheidt P; Zeier M et al.
Source: Self-asserted source
Carsten Grüllich via Europe PubMed Central

Docetaxel followed by abiraterone in metastatic castration-resistant prostate cancer: efficacy and predictive parameters in a large single center cohort.

World journal of urology
2014-08 | Journal article
Contributors: Höfner T; Vallet S; Hadaschik BA; Pahernik S; Duensing S; Hohenfellner M; Jäger D; Grüllich C
Source: Self-asserted source
Carsten Grüllich via Europe PubMed Central

Evolving therapeutic concepts in prostate cancer based on genome-wide analyses (review).

International journal of oncology
2014-07 | Journal article
Contributors: Georgi B; Korzeniewski N; Hadaschik B; Grüllich C; Roth W; Sültmann H; Pahernik S; Hohenfellner M; Duensing S
Source: Self-asserted source
Carsten Grüllich via Europe PubMed Central

The tyrosine kinase inhibitor nilotinib has antineoplastic activity in prostate cancer cells but up-regulates the ERK survival signal-Implications for targeted therapies.

Urologic oncology
2014-07 | Journal article
Contributors: Schneider M; Korzeniewski N; Merkle K; Schüler J; Grüllich C; Hadaschik B; Hohenfellner M; Duensing S
Source: Self-asserted source
Carsten Grüllich via Europe PubMed Central

Phenotypic drug screening and target validation for improved personalized therapy reveal the complexity of phenotype-genotype correlations in clear cell renal cell carcinoma.

Urologic oncology
2014-06 | Journal article
Contributors: Schneider M; Schüler J; Höfflin R; Korzeniewski N; Grüllich C; Roth W; Teber D; Hadaschik B; Pahernik S; Hohenfellner M et al.
Source: Self-asserted source
Carsten Grüllich via Europe PubMed Central

Excellent local control with IOERT and postoperative EBRT in high grade extremity sarcoma: results from a subgroup analysis of a prospective trial.

BMC cancer
2014-05 | Journal article
Contributors: Roeder F; Lehner B; Schmitt T; Kasper B; Egerer G; Sedlaczek O; Grüllich C; Mechtersheimer G; Wuchter P; Hensley FW et al.
Source: Self-asserted source
Carsten Grüllich via Europe PubMed Central

Rabbit anti-T-lymphocyte globulin (ATG) persists with differential reactivity in patients' sera after full hematopoetic regeneration from allogeneic stem cell transplantation.

Transplant immunology
2014-04 | Journal article
Contributors: Ziegler C; Finke J; Grüllich C
Source: Self-asserted source
Carsten Grüllich via Europe PubMed Central
Items per page:
Page 1 of 2